Timothy Fenske, MD, MS

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English

Contact Information

Education

MD - Doctor of Medicine
MS -Master of Science

Biography

Dr. Timothy Fenske attended medical school at the University of Wisconsin-Madison, where he also completed an MS degree in cellular and molecular biology. After completing a residency in internal medicine at UW-Madison, he then completed a fellowship in hematology and oncology at Washington University (Barnes Hospital) in St. Louis, where he was awarded a position on the National Institutes of Health Hematology Training Grant. He joined the faculty of the Medical College of Wisconsin in 2005 and is board-certified in internal medicine and medical oncology.

Research Interests

His clinical and research efforts are focused on the care of patients with Hodgkin lymphoma (Hodgkin's disease) and Non-Hodgkin lymphoma. He is particularly interested in innovative treatments for lymphoma, including novel pharmaceutical, immunological, and stem cell transplant therapies, as well as strategies to minimize the toxicity of therapy.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

(Shah NN, Ahn KW, Litovich CA, He Y, Sauter CS, Fenske TS, Hamadani M.) Blood. 2020 Oct 29 PMID: 33120429 10/30/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 10;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.

(Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M.) Biol Blood Marrow Transplant. 2020 Sep 19 PMID: 32956819 SCOPUS ID: 2-s2.0-85093981145 09/22/2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

(Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM.) Lancet Haematol. 2020 Sep;7(9):e660-e670 PMID: 32853585 PMCID: PMC7737486 08/28/2020
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.

(Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M.) Br J Haematol. 2020 08;190(4):573-582 PMID: 32314807 PMCID: PMC7575614 SCOPUS ID: 2-s2.0-85083643436 04/22/2020
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.

(Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT.) Biol Blood Marrow Transplant. 2020 06;26(6):1099-1105 PMID: 32165327 PMCID: PMC7255948 SCOPUS ID: 2-s2.0-85083523089 03/14/2020
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

(Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P.) Blood Adv. 2020 05 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.

(Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M.) Cancer. 2020 05 15;126(10):2279-2287 PMID: 32049359 PMCID: PMC7190439 SCOPUS ID: 2-s2.0-85079369077 02/13/2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.

(Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 05;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020
Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

(Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).) Biol Blood Marrow Transplant. 2020 04;26(4):e77-e85 PMID: 31917272 PMCID: PMC7207150 SCOPUS ID: 2-s2.0-85079050617 01/10/2020
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.

(Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS.) Blood Adv. 2020 01 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020